Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the pharmacokinetics, safety and tolerability of Crinecerfont in infants under 2 years with congenital adrenal hyperp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Crinecerfont (crinecerfont)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Congenital Adrenal Hyperplasia | Phase 2 | Status: RECRUITING